Chamutal Gur1, Orna Diav-Citrin, Svetlana Shechtman, Judy Arnon, Asher Ornoy. 1. The Israeli Teratogen Information Service, The Israeli Ministry of Health, Hadassah Medical School and The Israeli Ministry of Health, The Hebrew University, P.O. Box 12272, Jerusalem 91120, Israel.
Abstract
OBJECTIVE: To evaluate the safety of glucocorticosteroids (GCS) in pregnancy. STUDY DESIGN: The Israeli Teratogen Information Service (TIS) prospectively collected and followed 311 pregnancies counseled regarding systemic use of different GCS in the first trimester. The rate of major congenital anomalies was compared to that of 790 controls who were counseled for non-teratogenic exposure. RESULTS: The rate of major anomalies did not significantly differ between the groups [12/262 = 4.6% (GCS), 19/728 = 2.6% (control), [P = 0.116 ]. There was no case of oral cleft and no pattern of anomalies among the GCS exposed group. Higher rates of miscarriages (11.5% versus 7.0%, P = 0.013) and preterm births (22.7% versus 10.8%, P < 0.001 ) were observed among the GCS exposed group compared to the controls. GCS exposed infants had a lower median birth weight [3080 g versus 3290 g, P < 0.001 ] and were born at an earlier median gestational age [39 weeks versus 40, P < 0.001 ] compared to the control. CONCLUSIONS: The present study supports that GCS do not represent a major teratogenic risk in humans. The study was powered to find a 2.5-fold increase in the overall rate of major anomalies.
OBJECTIVE: To evaluate the safety of glucocorticosteroids (GCS) in pregnancy. STUDY DESIGN: The Israeli Teratogen Information Service (TIS) prospectively collected and followed 311 pregnancies counseled regarding systemic use of different GCS in the first trimester. The rate of major congenital anomalies was compared to that of 790 controls who were counseled for non-teratogenic exposure. RESULTS: The rate of major anomalies did not significantly differ between the groups [12/262 = 4.6% (GCS), 19/728 = 2.6% (control), [P = 0.116 ]. There was no case of oral cleft and no pattern of anomalies among the GCS exposed group. Higher rates of miscarriages (11.5% versus 7.0%, P = 0.013) and preterm births (22.7% versus 10.8%, P < 0.001 ) were observed among the GCS exposed group compared to the controls. GCS exposed infants had a lower median birth weight [3080 g versus 3290 g, P < 0.001 ] and were born at an earlier median gestational age [39 weeks versus 40, P < 0.001 ] compared to the control. CONCLUSIONS: The present study supports that GCS do not represent a major teratogenic risk in humans. The study was powered to find a 2.5-fold increase in the overall rate of major anomalies.
Authors: Rachel J Ryu; Thomas R Easterling; Steve N Caritis; Raman Venkataramanan; Jason G Umans; Mahmoud S Ahmed; Shannon Clark; Ira Kantrowitz-Gordon; Karen Hays; Brooke Bennett; Matthew T Honaker; Kenneth E Thummel; Danny D Shen; Mary F Hebert Journal: J Clin Pharmacol Date: 2018-05-07 Impact factor: 3.126
Authors: Hyoung Yoon Chang; Katherine M Keyes; Kyung-Sook Lee; In Ae Choi; Se Joo Kim; Kyung Won Kim; Youn Ho Shin; Kang Mo Ahn; Soo-Jong Hong; Yee-Jin Shin Journal: Early Hum Dev Date: 2013-12-10 Impact factor: 2.079
Authors: M Kunze; S Arndt; A Zimmer; M Földi; A Hanjalic-Beck; M Echternach; R Birkenhäger; A Aschendorff Journal: HNO Date: 2012-02 Impact factor: 1.284
Authors: María Emilia Solano; Megan C Holmes; Paul R Mittelstadt; Karen E Chapman; Eva Tolosa Journal: Semin Immunopathol Date: 2016-07-28 Impact factor: 9.623